Analyst Price Targets — ESTA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 31, 2025 9:24 am | Sam Eiber | BTIG | $86.00 | $72.92 | StreetInsider | Establishment Labs Inc. (ESTA) PT Raised to $86 at BTIG |
| December 17, 2025 12:14 pm | — | Canaccord Genuity | $85.00 | $74.15 | TheFly | Establishment Labs price target raised to $85 from $72 at Canaccord |
| December 10, 2025 11:06 am | Mike Matson | Needham | $84.00 | $71.01 | StreetInsider | Establishment Labs Inc. (ESTA) PT Raised to $84 at Needham |
| November 14, 2025 10:39 am | Sam Eiber | BTIG | $81.00 | $64.75 | StreetInsider | Establishment Labs Inc. (ESTA) PT Raised to $81 at BTIG |
| November 6, 2025 11:22 pm | — | Needham | $70.00 | $64.91 | TheFly | Establishment Labs price target raised to $70 from $48 at Needham |
| November 5, 2025 5:20 pm | Sam Eiber | BTIG | $70.00 | $59.55 | StreetInsider | Establishment Labs Inc. (ESTA) PT Raised to $70 at BTIG |
| August 22, 2024 5:50 am | Joanne Wuensch | Citigroup | $45.00 | $44.05 | TheFly | Citi opens 'positive catalyst watch' on Establishment Labs |
| June 6, 2024 6:34 am | Anthony Petrone | Mizuho Securities | $70.00 | $53.89 | StreetInsider | Establishment Labs Inc. (ESTA) PT Raised to $70 at Mizuho |
| April 1, 2024 6:34 am | Anthony Petrone | Mizuho Securities | $65.00 | $50.90 | StreetInsider | Establishment Labs Inc. (ESTA) PT Raised to $65 at Mizuho 'on the potential for US Motiva to receive FDA clearance' |
| December 28, 2022 8:09 am | — | Stephens | $87.00 | $60.45 | Benzinga | Stephens & Co. Maintains Overweight on Establishment Labs Hldgs, Lowers Price Target to $87 |
Latest News for ESTA
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.98 per share a year ago.
Establishment Labs Holdings Inc. (ESTA) Q4 2025 Earnings Call Transcript
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced a strategic leadership transition of Raj Denhoy, current Chief Financial Officer to Senior Vice President, Global Strategy, and the appointment of Cassandra “Sandra” Harris to Senior…
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided 2026 guidance. Fourth Quarter Highlights and Outlook Fourth quarter revenue of $64.6 million,…
Establishment Labs (NASDAQ: ESTA - Get Free Report) and Pediatrix Medical Group (NYSE: MD - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends. Profitability This table compares Establishment Labs and
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ESTA.
U.S. House Trading
No House trades found for ESTA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.